These results indicate that pre-screening of EGFR-wt NSCLC tumors for BRG1 status and pre-existence of the EGFR–AKT complex will aid in designing appropriate and improved treatment options for patients diagnosed with lung cancer. This evidence concerns the gene EGFR and lung cancer.